Rohit S Loomba1,2, Enrique G Villarreal3, Juan S Farias3, Gaurav Aggarwal4, Saurabh Aggarwal5, Saul Flores6,7. 1. Department of Pediatric Critical Care, Advocate Children's Hospital, Oak Lawn, IL, USA. 2. Department of Pediatrics, Chicago Medical School/Rosalind Franklin University of Medicine and Science, Chicago, IL, USA. 3. Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico. 4. Department of Medicine, Jersey City Medical Center, Jersey City, NJ, USA. 5. Department of Medicine, UnityPoint Clinic, Des Moines, IA, USA. 6. Department of Pediatrics, Texas Children's Hospital, Houston, TX, USA. 7. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: There is limited information regarding the role of biomarker levels at predicting mortality in patients with the coronavirus disease (COVID-19) pandemic. The purpose of this study is to determine the differences in serum biomarker levels in adults with COVID-19 who survived hospitalization from those who did not. METHODS: A comprehensive search was completed on PubMed, EMBASE and Cochrane libraries to identify studies of interest. Endpoints of interest were blood counts, hepatic function test, acute phase reactants, cytokines and cardiac biomarkers. RESULTS: A total of 10 studies with 1584 patients were included in the pooled analyses. Biomarkers that were noted to be significantly higher in those who died from coronavirus disease included: white blood cell count, neutrophil count, C-reactive protein, high sensitivity C-reactive protein, procalcitonin, ferritin, D-dimer, interleukin-6, lactate dehydrogenase, creatine kinase, prothrombin time, aspartate aminotransferase, alanine aminotransferase, total bilirubin and creatinine. Lymphocyte count, platelet count and albumin were significantly lower in patients who died. CONCLUSION: This pooled analysis of 10 studies including 1584 patients identified significant differences in biomarkers on admission in patients who survived from those who did not. Further research is needed to develop risk stratification models to help with judicious use of limited health-care resources.
BACKGROUND: There is limited information regarding the role of biomarker levels at predicting mortality in patients with the coronavirus disease (COVID-19) pandemic. The purpose of this study is to determine the differences in serum biomarker levels in adults with COVID-19 who survived hospitalization from those who did not. METHODS: A comprehensive search was completed on PubMed, EMBASE and Cochrane libraries to identify studies of interest. Endpoints of interest were blood counts, hepatic function test, acute phase reactants, cytokines and cardiac biomarkers. RESULTS: A total of 10 studies with 1584 patients were included in the pooled analyses. Biomarkers that were noted to be significantly higher in those who died from coronavirus disease included: white blood cell count, neutrophil count, C-reactive protein, high sensitivity C-reactive protein, procalcitonin, ferritin, D-dimer, interleukin-6, lactate dehydrogenase, creatine kinase, prothrombin time, aspartate aminotransferase, alanine aminotransferase, total bilirubin and creatinine. Lymphocyte count, platelet count and albumin were significantly lower in patients who died. CONCLUSION: This pooled analysis of 10 studies including 1584 patients identified significant differences in biomarkers on admission in patients who survived from those who did not. Further research is needed to develop risk stratification models to help with judicious use of limited health-care resources.
Authors: Adrian Matysek; Aneta Studnicka; Wade Menpes Smith; Michał Hutny; Paweł Gajewski; Krzysztof J Filipiak; Jorming Goh; Guang Yang Journal: Front Med (Lausanne) Date: 2022-08-01
Authors: Alex K Chen; Xiaoling Wang; Lynnette P McCluskey; John C Morgan; Jeffrey A Switzer; Rohini Mehta; Martha Tingen; Shaoyong Su; Ryan Alan Harris; David C Hess; Elizabeth K Rutkowski Journal: Brain Behav Immun Health Date: 2022-07-18